Table 3. Comparison of phenotypic characteristics found among populations.
| Characteristic (unit) | Pop1a | Pop2 | Pop3 | Pop4 | p | |
|---|---|---|---|---|---|---|
| Source c | Clinical | 3 | 50 | 18 | 3 | 0.014* |
| Environmental | 3 | 7 | 1 | 4 | ||
| Hemolytic Activity (Pz) d | 0.66 | 0.57 | 0.71 | 0.46 | 0.24 | |
| Phospholipases (Pz) d | 0.59 | 0.60 | 0.57 | 0.62 | 0.77 | |
| Proteases (Pz) d | 0.93 | 0.9 | 1.0 | 0.93 | 0.24 | |
| Gelatin Hydrolysis (Pz) d | 0.87 | 0.79 | 0.76 | 0.93 | 0.53 | |
| Visual Melanin Production c | High | 3 | 47 | 18 | 6 | 0.087 |
| Intermediate | 3 | 10 | 1 | 1 | ||
| Melanin Production (480 nm) d | 0.04 | 0.043 | 0.04 | 0.04 | 0.85 | |
| Urease (550 nm) d | 0.578 | 0.571 | 0.57 | 0.61 | 0.74 | |
| Yeast size SAB (μm) d | 6.3 | 5.95 | 6.38 | 6.68 | 0.53 | |
| Yeast size MOPS (μm) d | 6.1 | 5.43 | 6.40 | 5.78 | <0.0001* | |
| Capsule size SAB (μm) d | 1.04 | 1.18 | 1.02 | 0.99 | 0.097 | |
| Capsule size MOPS (μm) d | 3.01 | 3.21 | 2.52 | 2.7 | 0.36 | |
| Outcome c | Clinical Cure | 0 | 21 | 0 | 0 | 0.037* |
| Death | 3b | 28 | 1b | 3b | ||
| Gender c | Female | 0 | 12 | 0 | 0 | 0.533 |
| Male | 3 | 37 | 1 | 3 | ||
| Mean Age (years) d | 37 | 35.3 | 36 | 42 | 0.689 | |
| Origin c | Uberaba | 1 | 24 | 0 | 3 | 0.235 |
| Uberaba out | 2 | 21 | 1 | 0 |
Statistically significant differences among the groups are marked with * (p <0.05).
Legend: AB–absorbance; MOPS–Growth to evaluate the ability of capsular synthesis; SAB–Sabouraud dextrose growth.
a–The clinical and epidemiological results were not performed for one of Pop1 isolates.
b–These patients were summed to evaluate the clinical outcome in patients with ST93 and other ST’s.
c–Statistical analysis performed with the Fisher's exact test or Chi-square.
d–Statistical analysis performed with Kruskal-Wallis test applying the Dunn's post-test if necessary. Larger data are available in S3 Table.